Enrolling Now
Dupilumab Study for Pruritus of Lichen Simplex Chronicus in Adults in NYC
ENROLLING — This Phase 3, 2-arm study evaluates pruritus improvement with dupilumab injections versus placebo in adults with LSC.
Ruxolitinib Cream Study for Pediatric Nonsegmental Vitiligo in NYC
ENROLLING — This study evaluates the safety and efficacy of Ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
APG777 for Moderate to Severe Atopic Dermatitis Study in NYC
ENROLLING — This two-part study will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD).
Tildrakizumab for Moderate to Severe Genital Psoriasis Study in NYC
ENROLLING — Phase 3 study to evaluate the efficacy and safety of subcutaneous Tildrakizumab in subjects with moderate to severe genital psoriasis.
Ixekizumab and Tirzepatide for Plaque Psoriasis and Overweight Study in NYC
ENROLLING — Be part of our NYC study to explore the effects of Ixekizumab and Tirzepatide on individuals with plaque psoriasis and overweight.
Prurigo Nodularis Study With Opzelura in NYC
ENROLLING — Join our groundbreaking clinical trial in NYC for Prurigo Nodularis, testing Opzelura Cream's innovative treatment approach.
Hidradenitis Suppurativa Clinical Trial With Remibrutinib in NYC
ENROLLING — Join our clinical trial in NYC for moderate-to-severe Hidradenitis Suppurativa (HS) with Remibrutinib. Help advance HS treatment while receiving expert care.
Alopecia Areata Clinical Trial with Rinvoq in NYC
ENROLLING — Embark on our groundbreaking clinical trial in NYC for severe alopecia areata, where Rinvoq is being tested as a promising treatment.
Rinvoq vs. Dupixent for Atopic Dermatitis Study in NYC
ENROLLING — Be part of our SWITCH-UP Atopic Dermatitis trial in NYC to explore Rinvoq as an alternative for those unresponsive to Dupixent.
Clinical Trial Study for Atopic Dermatitis
ENROLLING — Learn more about our Amlitelimab trial targeting moderate-to-severe Atopic Dermatitis in NYC.
